WALTHAM, Mass.--(BUSINESS WIRE)-- BG Medicine, a life sciences company focused on the discovery, development, and commercialization of novel diagnostics, today announced the publication* of a study exploring the predictive value of plasma galectin-3 levels in heart failure (HF) patients with reduced and preserved ejection fraction.
The study was conducted by the Department of Cardiology at the University Medical Centre Groningen in The Netherlands. The results of this prospective study, in which 592 HF patients were studied, confirm that galectin-3 is a strong and independent predictor of adverse outcomes. The prognostic value of galectin-3 remained even after adjustment for established risk factors for poor outcomes in HF, including age, sex, BNP, renal function, and diabetes mellitus.
To download an abstract of the article and for more information, please visit the Galectin-3 website at www.galectin-3.com.
*Citation of the Publication: de Boer RA, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2010; Early Online, 1–9.
About BG Medicine
BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs.
Michael W. Rogers, 781-890-1199
EVP & Chief Financial Officer
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Cardiology Research Science